Ventana Developing Companion Diagnostic For Novartis’ Gleevec Cancer Drug
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical Systems expects to submit a premarket approval application by early next year for a c-kit diagnostic for use with Novartis' drug Gleevec (imatinib mesylate)
You may also be interested in...
Thomas Weisel Partners Healthcare Tailwinds Conference In Brief
Zimmer MIS strategy spurs hip, knee sales: The Zimmer Institute plans to increase the number of its hospital partners for teaching Zimmer MIS 2-Incision hip and MIS Quad-Sparing knee procedures to interested surgeons from eight to between 20 and 25, President & CEO Raymond Elliot states at the Thomas Weisel Partners Healthcare Tailwinds Conference in Boston Sept. 8. "MIS brings in...market share [at] hospitals, because they market that process. And it certainly gets you a lot of attention from surgeons that, I can assure you, we have not had attention from in the past," Elliot noted. The exec said excitement among the more than 1,500 surgeons who have been trained thus far by Zimmer and its contract partners played a critical role in the firm's ability to increase U.S. hip and knee revenue 20% and 21% to $127 mil. and $186 mil., respectively, in the second quarter (1"The Gray Sheet" Feb. 16, 2004, p. 9)...
Thomas Weisel Partners Healthcare Tailwinds Conference In Brief
Zimmer MIS strategy spurs hip, knee sales: The Zimmer Institute plans to increase the number of its hospital partners for teaching Zimmer MIS 2-Incision hip and MIS Quad-Sparing knee procedures to interested surgeons from eight to between 20 and 25, President & CEO Raymond Elliot states at the Thomas Weisel Partners Healthcare Tailwinds Conference in Boston Sept. 8. "MIS brings in...market share [at] hospitals, because they market that process. And it certainly gets you a lot of attention from surgeons that, I can assure you, we have not had attention from in the past," Elliot noted. The exec said excitement among the more than 1,500 surgeons who have been trained thus far by Zimmer and its contract partners played a critical role in the firm's ability to increase U.S. hip and knee revenue 20% and 21% to $127 mil. and $186 mil., respectively, in the second quarter (1"The Gray Sheet" Feb. 16, 2004, p. 9)...
Erbitux Companion Test Approval Clears Path For Further Co-Development
DakoCytomation expects reimbursement policies for ImClone's Erbitux colorectal cancer drug to guide adoption of companion diagnostic EGFR pharmDx